Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
First and only PARP inhibitor to improve overall survival in early breast cancer
First and only PARP inhibitor to improve overall survival in early breast cancer
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Subscribe To Our Newsletter & Stay Updated